YD Bio Limited Ordinary Shares

TAIPEI, Taiwan, and BOTHELL, Wash., Oct. 20, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection and ophthalmologic innovations, today announced a strategic collaboration with EG BioMed Co., Ltd., a Taiwan registered company and an affiliate of YD Bio (“EG BioMed”), and digital health provider JoiiUp. The partnership integrates an AI Cancer Risk Assessment (the “Assessment”), jointly developed by YD Bio and EG BioMed, into JoiiUp's JoiiSports app, expanding access to personalized health insights for corporate wellness programs and healthcare institutions.

YD Bio Limited (NASDAQ: YDES - Get Free Report) was the recipient of a large growth in short interest in the month of September. As of September 30th, there was short interest totaling 177,332 shares, a growth of 312.8% from the September 15th total of 42,960 shares. Based on an average daily trading volume, of 728,505

TAIPEI, Taiwan, and BOTHELL, Wash., Oct. 06, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company and EG BioMed Co., Ltd.

YD Bio Limited (NASDAQ: YDES - Get Free Report)'s share price dropped 4.4% during mid-day trading on Wednesday. The stock traded as low as $6.80 and last traded at $7.2760. 68,234 shares changed hands during mid-day trading, a decline of 52% from the average daily volume of 141,640 shares. The stock had previously closed at $7.61.